302 patents
Page 4 of 16
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES As Dipeptidyl Peptidase 1 Inhibitors
13 Apr 23
Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
Filed: 10 Sep 22
Utility
Compounds and Their Use
13 Apr 23
Lars Anders Mikael JOHANSSON, Giulia BERGONZINI, Henrik GRADÉN, Hiroshi SUGAMA, Takehiko MATSUMURA
Filed: 1 Jul 22
Utility
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
28 Mar 23
Bernard Christophe Barlaam, Kurt Gordon Pike, Andrew John Eatherton, Thomas Anthony Hunt
Filed: 1 Dec 20
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES As Dipeptidyl Peptidase 1 Inhibitors
23 Mar 23
Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
Filed: 10 Sep 22
Utility
Compounds and Their Use
16 Mar 23
The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein.
Kenneth Lars GRANBERG, Shigeki SAKAMAKI, Ryuichi FUCHIGAMI, Yasuki NIWA, Masakazu FUJIO, Hans Fredrik BERGSTRÖM, Stig Jonas BOSTRÖM
Filed: 7 Dec 21
Utility
PCSK9 inhibitors and methods of use thereof
14 Mar 23
The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.
Michael H. Serrano-Wu, Brian K. Hubbard, Virendar Kaushik, Doug Daniels
Filed: 16 Jan 20
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES As Dipeptidyl Peptidase 1 Inhibitors
2 Mar 23
Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
Filed: 15 Sep 22
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES As Dipeptidyl Peptidase 1 Inhibitors
2 Mar 23
Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
Filed: 9 Sep 22
Utility
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
23 Feb 23
The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of cancer, wherein the EGFR TKI is administered in combination with a Smac mimetic.
Nicolas FLOCH, Paul David SMITH, Matthew Joseph MARTIN
Filed: 19 Jan 21
Utility
Process and Intermediates for the Production of Formula (I)
16 Feb 23
Jerome DUBIEZ, Andrew TURNER, Richard CHUBB
Filed: 4 Dec 20
Utility
Combination Therapy for Treating Cancer
9 Feb 23
The present disclosure relates, in general, to therapeutic combinations of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one and olaparib, and to corresponding methods of treatment, pharmaceutical compositions, and kits.
Maureen HATTERSLEY, Gayle Pageau POULIOT, Huawei Raymond CHEN, Serena DE VITA
Filed: 8 Jan 21
Utility
[1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases
2 Feb 23
Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
Filed: 29 Jun 22
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES As Dipeptidyl Peptidase 1 Inhibitors
2 Feb 23
Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
Filed: 10 Sep 22
Utility
CorrectedDose Dumping Resistant Pharmaceutical Compositions Comprising Verinurad
2 Feb 23
Disclosed herein are pharmaceutical formulations comprising verinurad or a pharmaceutically acceptable salt thereof that are resistant to alcohol-induced dose dumping and may be used in therapeutic and/or prophylactic methods.
Christian von Corswant, Laleh Maleki
Filed: 15 Jul 20
Utility
Combination Therapy for Treating a Hematological Malignancy
26 Jan 23
Disclosed are methods of treating cancer comprising administering to a subject in need thereof an effective amount of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof and an effective amount of venetoclax or a pharmaceutically acceptable salt thereof.
Maureen Hattersley, Courtney Andersen, Huawei Raymond Chen
Filed: 12 Oct 20
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES As Dipeptidyl Peptidase 1 Inhibitors
26 Jan 23
Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
Filed: 10 Sep 22
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES As Dipeptidyl Peptidase 1 Inhibitors
26 Jan 23
Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
Filed: 10 Sep 22
Utility
Methods for Preventing or Treating Certain Disorders by Inhibiting Binding of IL-4 And/or IL-13 to Their Respective Receptors
19 Jan 23
The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof.
Andreas Hohlbaum, Laurent Audoly, Beverly Koller
Filed: 14 Jun 22
Utility
Pharmaceutical Composition Comprising a Potent Inhibitor of URAT1
12 Jan 23
The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Joanne REILAND WAKEMAN, Colin ROWLINGS, Sha LIU, Gerry BURKE, Christian VON CORSWANT, Christer TANNERGREN, Johan HJÄRTSTAM
Filed: 23 Jun 22
Utility
Solid Pharmaceutical Formulations of 6-(2-CHLORO-6-METHYLPYRIDIN-4-YL)-5-(4-FLUOROPHENYL)-1,2,4-TRIAZIN-3-AMINE
5 Jan 23
Solid pharmaceutical formulations including AZD4635 are described.
Anders HOLMGREN, Annika KYSSÄ, Christian VON CORSWANT, Urban SKANTZE
Filed: 1 Dec 20